Drug Price Trends for NDC 50742-0175

Average Pharmacy Cost for 50742-0175

Drug Name	NDC	Price/Unit ($)	Unit	Date
ISOSORBIDE MONONIT ER 30 MG TB	50742-0175-01	0.07064	EACH	2026-03-18
ISOSORBIDE MONONIT ER 30 MG TB	50742-0175-05	0.07064	EACH	2026-03-18
ISOSORBIDE MONONIT ER 30 MG TB	50742-0175-01	0.07002	EACH	2026-02-18
ISOSORBIDE MONONIT ER 30 MG TB	50742-0175-05	0.07002	EACH	2026-02-18

Best Wholesale Price for NDC 50742-0175

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
ISOSORBIDE MONONITRATE 30MG TAB,SA	Golden State Medical Supply, Inc.	50742-0175-01	100	5.75	0.05750	2023-06-15 - 2028-06-14	FSS
ISOSORBIDE MONONITRATE 30MG TAB,SA	Golden State Medical Supply, Inc.	50742-0175-05	500	27.03	0.05406	2023-06-15 - 2028-06-14	FSS

Market Dynamics and Price Projections for Ndc: 50742-0175

Last updated: February 19, 2026

This report analyzes the current market landscape and projects future pricing for the drug with National Drug Code (NDC) 50742-0175. The analysis focuses on factors influencing supply, demand, regulatory environment, and competitive pressures that will shape market access and pricing strategies.

What is the Current Market Position of Ndc: 50742-0175?

Ndc: 50742-0175 is a prescription drug indicated for the treatment of [Therapeutic Area of Ndc: 50742-0175]. As of [Current Month, Year], the drug is available from [Number] manufacturers, with [Manufacturer Name 1] holding the largest market share at approximately [Percentage]%. The primary distribution channels are retail pharmacies ([Percentage]%) and mail-order pharmacies ([Percentage]%).

The market is characterized by [mention key market characteristics, e.g., moderate to high demand, limited competition, established patient base, emerging patient population, etc.]. The average wholesale price (AWP) for a [Dosage Form, e.g., 30-day supply] of Ndc: 50742-0175 is currently $[Current AWP Price] as of [Date of AWP data]. This represents a [Percentage]% change from the AWP recorded in [Previous Year].

Prescription volume for Ndc: 50742-0175 in the last [Time Period, e.g., 12 months] was approximately [Number] prescriptions. This volume is driven by [mention key drivers, e.g., a diagnosed patient population of X, increasing incidence of Y disease, physician prescribing habits, etc.].

The drug's patent status is [Patent Status, e.g., still under patent protection, has generic competition, patent expiration date]. [If patent protection is in place, state expiry date and any extension details. If generic competition exists, state the number of generic competitors and their entry dates.]

Table 1: Key Market Indicators for Ndc: 50742-0175 (As of [Current Month, Year])

Indicator	Value
Primary Indication	[Therapeutic Area]
Number of Manufacturers	[Number]
Leading Manufacturer	[Manufacturer Name]
Leading Manufacturer Market Share	[Percentage]%
Primary Distribution Channels	Retail, Mail-Order
Average Wholesale Price (AWP)	$[Current AWP Price]
Prescription Volume (Last 12 Months)	[Number]
Patent Status	[Patent Status]

What Factors Will Influence Future Pricing?

Several key factors will influence the future pricing of Ndc: 50742-0175. These include regulatory actions, market competition, patient access programs, and evolving treatment paradigms.

Will Regulatory Changes Impact Pricing?

Regulatory actions, particularly those from the Food and Drug Administration (FDA) and the Centers for Medicare & Medicaid Services (CMS), can significantly affect drug pricing.

• FDA Actions: Any new indications approved by the FDA for Ndc: 50742-0175 could expand its patient population and potentially support higher pricing. Conversely, post-market surveillance revealing safety concerns could lead to labeling changes or restrictions, potentially decreasing demand and pricing power. As of [Date of FDA data review], there are [Number] pending supplemental New Drug Applications (sNDAs) for Ndc: 50742-0175.
• CMS Policies: CMS price negotiation policies, if enacted or expanded, could directly impact reimbursement rates for Ndc: 50742-0175, especially for Medicare beneficiaries. The Inflation Reduction Act of 2022 (IRA) allows Medicare to negotiate prices for certain high-cost drugs. Ndc: 50742-0175 [does/does not] meet the current criteria for Medicare negotiation under the IRA due to [reason, e.g., its launch date, expenditure threshold, or therapeutic class]. Future adjustments to these criteria could alter this status.
• Drug Pricing Transparency Initiatives: Increased regulatory pressure for drug pricing transparency may lead to greater scrutiny of price increases. [Mention any specific transparency laws relevant to the drug's market, e.g., state-level disclosure requirements.]

How Will Competition Affect Pricing?

The competitive landscape is a primary driver of pricing dynamics.

• Generic Entry: The expected entry of generic competitors for Ndc: 50742-0175 is projected for [Year of Generic Entry if applicable]. Based on typical market erosion patterns following generic launches, pricing could decrease by [Percentage]% to [Percentage]% within [Number] years of the first generic's availability. Currently, there are [Number] ANDA applications pending for generics.
• Biosimilar Competition: If Ndc: 50742-0175 is a biologic, the emergence of biosimilars would introduce similar pricing pressures. The first biosimilar for [Relevant Biologic if applicable] entered the market in [Year], resulting in an average price reduction of [Percentage]%.
• New Therapies: The development and launch of novel therapies within the same therapeutic area could siphon market share from Ndc: 50742-0175, forcing price adjustments to remain competitive. [Mention any specific new therapies in development or recently launched that are direct competitors, including their expected launch timelines or actual launch dates.]

Table 2: Competitive Landscape Analysis

Competitor Type	Number of Entities	Projected Impact on Pricing	Timeline
Generic	[Number]	[Percentage]% to [Percentage]% decrease	[Number] Years Post-Entry
Biosimilar	[Number]	[Percentage]% to [Percentage]% decrease	[Number] Years Post-Entry
New Therapies	[Number]	Moderate to High pressure	Ongoing

What is the Impact of Patient Access and Reimbursement?

Patient access programs and payer reimbursement policies directly influence the effective price paid for Ndc: 50742-0175.

• Payer Negotiations: Payer formulary placement and rebate agreements are critical. Payers are increasingly employing value-based contracting and seeking evidence of real-world effectiveness. Manufacturers will need to demonstrate a strong pharmacoeconomic profile to secure favorable formulary access and limit prior authorization requirements. As of [Date of Payer Data Review], [Percentage]% of covered lives for Ndc: 50742-0175 are covered by plans with preferred formulary status.
• Patient Assistance Programs: Manufacturer-sponsored patient assistance programs (PAPs) can shield patients from high out-of-pocket costs, thereby indirectly supporting higher list prices. These programs may face increased scrutiny regarding their impact on overall drug spending.
• Copay Accumulators/Maximizers: The proliferation of copay accumulator and maximizer programs by some health plans reduces the value of manufacturer copay coupons, potentially leading to increased patient cost-sharing and demand sensitivity. This trend impacts approximately [Percentage]% of commercial insurance plans.

How Will Evolving Treatment Paradigms Affect Demand?

Shifts in clinical guidelines and evolving patient expectations will also shape the market for Ndc: 50742-0175.

• Clinical Guidelines: Updates to treatment guidelines by professional medical societies can favor or disfavor Ndc: 50742-0175. For example, if new guidelines recommend alternative therapies as first-line treatments, demand for Ndc: 50742-0175 could decline. [Mention any relevant clinical guideline updates from major societies, e.g., American College of Cardiology, American Society of Clinical Oncology.]
• Patient Preferences: Growing patient demand for less invasive treatments or therapies with fewer side effects can influence prescribing patterns and thus market demand.
• Real-World Evidence: The availability of robust real-world evidence demonstrating long-term efficacy and safety will become increasingly important for payers and prescribers in evaluating the value proposition of Ndc: 50742-0175.

What Are the Price Projections for Ndc: 50742-0175?

Based on the confluence of these factors, the pricing trajectory for Ndc: 50742-0175 can be projected.

Short-Term Projection (1-3 Years): In the short term, pricing for Ndc: 50742-0175 is expected to remain relatively stable, with potential annual increases in line with inflation and modest market expansion. We project an average annual price increase of [Percentage]% to [Percentage]% driven by ongoing demand and the absence of immediate generic competition. The AWP is projected to reach $[Projected AWP Year 1] by [Year 1] and $[Projected AWP Year 3] by [Year 3]. This assumes no significant adverse regulatory actions or unexpected competitive entries.

Medium-Term Projection (3-7 Years): The medium term will be significantly influenced by the potential entry of generic competitors and the impact of evolving payer strategies. If generic entry occurs as anticipated in [Year of Generic Entry], a substantial price erosion is expected. The AWP could decline by [Percentage]% to [Percentage]% in the years following generic launch. This scenario anticipates that the brand will maintain a smaller, premium market segment for patients seeking the original product, while generics capture the majority of the volume.

Long-Term Projection (7+ Years): Beyond seven years, the market for Ndc: 50742-0175 will likely be dominated by generics, with the brand retaining a niche. Pricing will be largely dictated by the cost-competitiveness of generic manufacturers. The AWP of the brand may stabilize at a significantly reduced level, or the drug may transition to over-the-counter status if regulatory pathways permit and market conditions warrant.

Table 3: Projected AWP for Ndc: 50742-0175 (per [Dosage Form])

Timeframe	Projected AWP	Key Influencing Factors
[Current Year]	$[Current AWP Price]	Current market conditions, patent protection
[Year 1]	$[Projected AWP Year 1]	Inflationary adjustments, continued demand
[Year 3]	$[Projected AWP Year 3]	Stable demand, potential for early generic rumblings
[Year 5] (Post-Generic Entry)	$[Projected AWP Year 5 Post-Generic]	Significant price erosion due to generic competition
[Year 7]	$[Projected AWP Year 7]	Mature generic market, potential niche for brand product

Scenario Analysis:

• Optimistic Scenario (for Brand Manufacturer): Delayed generic entry, successful expansion into new indications, and robust payer coverage for the branded product. This could lead to sustained higher pricing for an extended period.
• Pessimistic Scenario (for Brand Manufacturer): Early generic entry, unexpected safety concerns leading to market withdrawal or severe restrictions, and aggressive payer mandates for generics. This would result in rapid and significant price decline.
• Base Case Scenario: The projections outlined above represent the most probable outcome, balancing patent expirations with ongoing market demand and competitive pressures.

Key Takeaways

• Ndc: 50742-0175 is currently positioned in a market characterized by [briefly reiterate market position] with a current AWP of $[Current AWP Price].
• Future pricing will be shaped by FDA actions, CMS negotiation policies, generic and biosimilar competition, payer strategies, and evolving clinical treatment paradigms.
• Generic entry, projected for [Year of Generic Entry], is anticipated to cause significant price erosion, reducing the AWP by [Percentage]% to [Percentage]% within [Number] years of launch.
• Short-term pricing is projected to increase by [Percentage]% to [Percentage]% annually, while long-term pricing will be predominantly dictated by generic market dynamics.

Frequently Asked Questions

1. What is the current patent expiration date for Ndc: 50742-0175? The patent protection for Ndc: 50742-0175 is scheduled to expire on [Patent Expiration Date].

2. Are there any biosimilars currently approved or in development for Ndc: 50742-0175? As of [Date of review], there are [Number] biosimilars approved or in [Stage of Development, e.g., Phase III clinical trials] for [mention if it is a biologic and the originator product if applicable].

3. What is the expected impact of the Inflation Reduction Act on Ndc: 50742-0175's pricing? Ndc: 50742-0175 currently [does/does not] meet the criteria for Medicare negotiation under the IRA. Future price negotiations may apply if criteria are adjusted or if the drug's expenditure profile changes significantly.

4. How does the current AWP of Ndc: 50742-0175 compare to similar drugs in its therapeutic class? The current AWP of $[Current AWP Price] places Ndc: 50742-0175 in the [e.g., mid-to-high, competitive] price range when compared to other drugs indicated for [Therapeutic Area], such as [Competitor Drug 1] with an AWP of $[Competitor Drug 1 AWP] and [Competitor Drug 2] with an AWP of $[Competitor Drug 2 AWP].

5. What are the primary patient access challenges for Ndc: 50742-0175? Challenges include navigating complex payer formularies, potential prior authorization requirements, and managing out-of-pocket costs, particularly with the increasing use of copay accumulator and maximizer programs.

Citations

[1] [Source 1 Name/Description], [Year of Publication/Access]. (e.g., IQVIA MIDAS Data, 2023; FDA Orange Book Database, accessed October 26, 2023; Manufacturer Press Release, [Date]). [2] [Source 2 Name/Description], [Year of Publication/Access]. [3] [Source 3 Name/Description], [Year of Publication/Access]. [4] [Source 4 Name/Description], [Year of Publication/Access]. [5] [Source 5 Name/Description], [Year of Publication/Access]. [6] [Source 6 Name/Description], [Year of Publication/Access]. [7] [Source 7 Name/Description], [Year of Publication/Access]. [8] [Source 8 Name/Description], [Year of Publication/Access]. [9] [Source 9 Name/Description], [Year of Publication/Access]. [10] [Source 10 Name/Description], [Year of Publication/Access].